20,597 Shares in Nkarta, Inc. (NASDAQ:NKTX) Bought by SG Americas Securities LLC

SG Americas Securities LLC bought a new stake in Nkarta, Inc. (NASDAQ:NKTX) during the 3rd quarter, Holdings Channel.com reports. The fund bought 20,597 shares of the company’s stock, valued at approximately $93,000.

A number of other large investors have also added to or reduced their stakes in the company. RA Capital Management L.P. raised its stake in shares of Nkarta by 38.4% during the 1st quarter. RA Capital Management L.P. now owns 10,805,129 shares of the company’s stock worth $116,803,000 after acquiring an additional 3,000,000 shares in the last quarter. SR One Capital Management LP boosted its stake in Nkarta by 150.0% in the first quarter. SR One Capital Management LP now owns 3,333,333 shares of the company’s stock valued at $36,033,000 after acquiring an additional 2,000,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in Nkarta by 26.0% in the first quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock worth $21,255,000 after purchasing an additional 405,753 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Nkarta by 12.0% during the second quarter. Renaissance Technologies LLC now owns 912,872 shares of the company’s stock worth $5,395,000 after purchasing an additional 98,000 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Nkarta during the 1st quarter valued at $9,072,000. 80.54% of the stock is currently owned by institutional investors.

Nkarta Stock Performance

Shares of NKTX stock opened at $3.46 on Tuesday. Nkarta, Inc. has a fifty-two week low of $1.86 and a fifty-two week high of $16.24. The firm has a market capitalization of $244.14 million, a PE ratio of -1.72 and a beta of 0.80. The stock’s 50-day simple moving average is $4.77 and its 200-day simple moving average is $5.82.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.15. Sell-side analysts forecast that Nkarta, Inc. will post -1.92 earnings per share for the current year.

Analysts Set New Price Targets

NKTX has been the topic of several research analyst reports. Rodman & Renshaw assumed coverage on Nkarta in a research note on Wednesday, October 9th. They set a “buy” rating and a $14.00 target price on the stock. HC Wainwright lowered their price target on Nkarta from $23.00 to $22.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Needham & Company LLC restated a “buy” rating and set a $13.00 price objective on shares of Nkarta in a report on Wednesday, August 14th. Raymond James raised shares of Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 price objective for the company in a research report on Wednesday, August 14th. Finally, RODMAN&RENSHAW raised shares of Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Nkarta has an average rating of “Buy” and a consensus target price of $17.50.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.